Thursday, December 08, 2011 10:11:56 AM
Ecology Coatings Develops UV-Curable Coatings for Medical Wristbands
Ecology Coatings, Inc. (OTCQB:ECOC), a leader in the discovery and development of nanotechnology-enabled, ultraviolet-curable advanced coatings, today announced it has developed a UV-curable coating to meet the rigorous requirements of the healthcare industry. The coating is applied to a multilayered paper, printable patient wristband and is benzophenone free—a request that is becoming a requirement within the food industry and is increasing in popularity within the healthcare sector.
"A major U.S. label manufacturer, searching for improved product performance, asked that we develop a UV-curable coating for patient identification wristbands used by their customers within the healthcare industry," commented Ecology Coatings CEO Bob Crockett. "Sally Ramsey, our Vice President of Research and Development, worked with the manufacturer to understand the use, durability and longevity of the wristbands in a hospital. Based on the data gathered, Ms. Ramsey and her staff developed a coating that would be clear, glossy and resistant to water, blood, urine, betadine, alcohol, xylene, acetone, antimicrobial skin cleansers, chlorhexidine and a number of other common chemicals that could come in contact with patient wristbands."
The company performed extensive laboratory trials before providing the coating to the label manufacturer for customer testing. According to Ms. Ramsey, the results, just received from the customer, were outstanding and the project is moving to the next level. AHA statistics from 2009 indicate there are approximately 5,800 registered hospitals in the U.S. with 944,000 staffed beds and 37 million annual patient admissions—all requiring patient identification wristbands.
"We are working closely with label manufacturers and believe the healthcare industry could be another excellent market for our coatings, from final overcoat on printable, multilayered paper wristbands to prescription labels," added Crockett.
There are many applications that will benefit from Ecology Coatings' UV-curable products. To discover if these environmentally friendly, UV-curable coatings can advance your manufacturing application or enhance your products, visit the company's website at www.ecologycoatings.com or send an email to sales@ecologycoatings.com.
About Ecology Coatings, Inc.
Ecology Coatings, Inc. (OTCQB: ECOC) is a leader in the development and licensing of cleantech ultraviolet (UV) curable coatings — coatings that improve the products we use daily. Ecology's technology platform allows manufacturers to enhance the durability and performance of their products, while significantly reducing energy costs and increasing manufacturing throughput. The company produces solvent-free coatings, which eliminate the escape of harmful solvents into the atmosphere during application. Headquartered in Warren, Michigan, Ecology Coatings has a development and prototype lab in Akron, Ohio. For additional information, visit the company's website at http://www.ecologycoatings.com.
http://ih.advfn.com/p.php?pid=nmona&article=50355147
Recent ABVC News
- AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share • GlobeNewswire Inc. • 04/18/2024 01:25:00 PM
- ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M • GlobeNewswire Inc. • 04/17/2024 01:00:00 PM
- ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M • GlobeNewswire Inc. • 04/10/2024 12:30:00 PM
- ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M • GlobeNewswire Inc. • 03/26/2024 12:30:00 PM
- AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update • GlobeNewswire Inc. • 03/14/2024 01:30:31 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/29/2024 09:32:35 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/29/2024 09:31:06 PM
- ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/16/2024 10:04:42 PM
- ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues • GlobeNewswire Inc. • 02/15/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:59:14 AM
- ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) • GlobeNewswire Inc. • 02/12/2024 01:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:04:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 02:30:48 PM
- ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share • GlobeNewswire Inc. • 02/08/2024 02:17:05 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/17/2024 10:01:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:30:12 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 10:01:27 PM
- ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees • GlobeNewswire Inc. • 01/03/2024 12:24:57 PM
- ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study • GlobeNewswire Inc. • 12/07/2023 01:30:00 PM
- ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials • GlobeNewswire Inc. • 12/05/2023 01:30:00 PM
- ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market • GlobeNewswire Inc. • 11/21/2023 01:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM